三友醫療(688085.SH):水木天蓬授權美敦力在內地獨家代理超聲骨刀系列產品
格隆匯5月24日丨三友醫療(688085.SH)公佈,近日,為了進一步促進超聲骨刀系列產品的市場推廣和銷售,提升市場佔有率,公司控股子公司北京水木天蓬醫療技術有限公司(簡稱“水木天蓬”)與上海美敦力智康醫療器械有限公司(簡稱“美敦力”)簽署了《獨家經銷協議》。
根據協議約定:水木天蓬授權美敦力在中國大陸地區內以獨家的方式推廣、營銷、銷售和經銷所有授權產品,授權產品為超聲骨刀設備FD880A、XD880A和其配套刀頭及其他耗材。協議的有效期為生效日至2024年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.